Asia-Pacific Enteric Disease Testing Market Databank
The Enteric Disease Testing market was valued at $1,725.2 Million in 2020, and is projected to reach $2,559.3 Million by 2029 growing at a CAGR of 4.53% from 2021 to 2029. E. Coli segment is expected to be the highest contributor to this market, with $575.5 Million in 2020, and is anticipated to reach $770.6 Million by 2029, registering a CAGR of 3.34%. Listeria segment is anticipated to reach $353.8 Million by 2029 with the highest CAGR of 5.79%. E. Coli and Salmonella segments collectively expected to account for about 56.7% share of the Enteric Disease Testing market in 2020, with the former constituting around 33.4% share. Listeria and Campylobacter segments are expected to witness significant growth rates at a CAGR of 5.79% and 5.66% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 29.3% in the overall Enteric Disease Testing market in 2020, and is anticipated to reach 32.5% by 2029.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook